Results
|
|
421.
|
|
|
|
422.
|
Novel multi-targeted ErbB family inhibitor afatinib blocks EGF-induced signaling and induces apoptosis in neuroblastoma. [electronic resource] by
- Mao, Xinfang
- Chen, Zhenghu
- Zhao, Yanling
- Yu, Yang
- Guan, Shan
- Woodfield, Sarah E
- Vasudevan, Sanjeev A
- Tao, Ling
- Pang, Jonathan C
- Lu, Jiaxiong
- Zhang, Huiyuan
- Zhang, Fuchun
- Yang, Jianhua
Producer: 20180326
In:
Oncotarget vol. 8
Availability: No items available.
|
|
|
423.
|
|
|
|
424.
|
|
|
|
425.
|
Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience. [electronic resource] by
- Kudo, Kenichiro
- Hotta, Katsuyuki
- Bessho, Akihiro
- Nogami, Naoyuki
- Kozuki, Toshiyuki
- Kuyama, Shoichi
- Inoue, Koji
- Harita, Shingo
- Okada, Toshiaki
- Gemba, Kenichi
- Fujii, Masanori
- Takigawa, Nagio
- Oda, Naohiro
- Tanimoto, Mitsune
- Kiura, Katsuyuki
Producer: 20170206
In:
Cancer chemotherapy and pharmacology vol. 77
Availability: No items available.
|
|
|
426.
|
Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase Inhibitors. [electronic resource] by
- Rossi, Sabrina
- Toschi, Luca
- Finocchiaro, Giovanna
- Di Noia, Vincenzo
- Bonomi, Maria
- Cerchiaro, Eleonora
- Ceresoli, Giovanni Luca
- Beretta, Giordano Domenico
- D'Argento, Ettore
- Santoro, Armando
Producer: 20190625
In:
Clinical lung cancer vol. 20
Availability: No items available.
|
|
|
427.
|
First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression. [electronic resource] by
- Schuler, Martin
- Tan, Eng-Huat
- O'Byrne, Kenneth
- Zhang, Li
- Boyer, Michael
- Mok, Tony
- Hirsh, Vera
- Yang, James Chih-Hsin
- Lee, Ki Hyeong
- Lu, Shun
- Shi, Yuankai
- Kim, Sang-We
- Laskin, Janessa
- Kim, Dong-Wan
- Arvis, Catherine Dubos
- Kölbeck, Karl
- Massey, Dan
- Märten, Angela
- Paz-Ares, Luis
- Park, Keunchil
Producer: 20190612
In:
Journal of cancer research and clinical oncology vol. 145
Availability: No items available.
|
|
|
428.
|
|
|
|
429.
|
Covalent inhibitors of EGFR family protein kinases induce degradation of human Tribbles 2 (TRIB2) pseudokinase in cancer cells. [electronic resource] by
- Foulkes, Daniel M
- Byrne, Dominic P
- Yeung, Wayland
- Shrestha, Safal
- Bailey, Fiona P
- Ferries, Samantha
- Eyers, Claire E
- Keeshan, Karen
- Wells, Carrow
- Drewry, David H
- Zuercher, William J
- Kannan, Natarajan
- Eyers, Patrick A
Producer: 20191031
In:
Science signaling vol. 11
Availability: No items available.
|
|
|
430.
|
|
|
|
431.
|
Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations. [electronic resource] by
- Janjigian, Yelena Y
- Smit, Egbert F
- Groen, Harry J M
- Horn, Leora
- Gettinger, Scott
- Camidge, D Ross
- Riely, Gregory J
- Wang, Bushi
- Fu, Yali
- Chand, Vikram K
- Miller, Vincent A
- Pao, William
Producer: 20160602
In:
Cancer discovery vol. 4
Availability: No items available.
|
|
|
432.
|
|
|
|
433.
|
|
|
|
434.
|
First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases. [electronic resource] by
- Schuler, Martin
- Wu, Yi-Long
- Hirsh, Vera
- O'Byrne, Kenneth
- Yamamoto, Nobuyuki
- Mok, Tony
- Popat, Sanjay
- Sequist, Lecia V
- Massey, Dan
- Zazulina, Victoria
- Yang, James C-H
Producer: 20170104
In:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer vol. 11
Availability: No items available.
|
|
|
435.
|
HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer. [electronic resource] by
- Canonici, Alexandra
- Ivers, Laura
- Conlon, Neil T
- Pedersen, Kasper
- Gaynor, Nicola
- Browne, Brigid C
- O'Brien, Neil A
- Gullo, Giuseppe
- Collins, Denis M
- O'Donovan, Norma
- Crown, John
Producer: 20200220
In:
Investigational new drugs vol. 37
Availability: No items available.
|
|
|
436.
|
A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. [electronic resource] by
- Eskens, F A L M
- Mom, C H
- Planting, A S T
- Gietema, J A
- Amelsberg, A
- Huisman, H
- van Doorn, L
- Burger, H
- Stopfer, P
- Verweij, J
- de Vries, E G E
Producer: 20080325
In:
British journal of cancer vol. 98
Availability: No items available.
|
|
|
437.
|
Afatinib prolongs survival compared with gefitinib in an epidermal growth factor receptor-driven lung cancer model. [electronic resource] by
- Ninomiya, Takashi
- Takigawa, Nagio
- Ichihara, Eiki
- Ochi, Nobuaki
- Murakami, Toshi
- Honda, Yoshihiro
- Kubo, Toshio
- Minami, Daisuke
- Kudo, Kenichiro
- Tanimoto, Mitsune
- Kiura, Katsuyuki
Producer: 20131210
In:
Molecular cancer therapeutics vol. 12
Availability: No items available.
|
|
|
438.
|
HER2 activating mutations are targets for colorectal cancer treatment. [electronic resource] by
- Kavuri, Shyam M
- Jain, Naveen
- Galimi, Francesco
- Cottino, Francesca
- Leto, Simonetta M
- Migliardi, Giorgia
- Searleman, Adam C
- Shen, Wei
- Monsey, John
- Trusolino, Livio
- Jacobs, Samuel A
- Bertotti, Andrea
- Bose, Ron
Producer: 20160505
In:
Cancer discovery vol. 5
Availability: No items available.
|
|
|
439.
|
|
|
|
440.
|
|